share_log

BeyondSpring Presents Final Phase 3 Results For Plinabulin In 2L/3L NSCLC At ISLAC 2024, With Concurrent Publication In The Lancet Respiratory Medicine

Benzinga ·  Sep 10, 2024 19:44
  • Statistically Significant and Clinically Meaningful Efficacy Data with Favorable Benefit/Risk ratio from DUBLIN-3 Phase 3 Study of Plinabulin plus Docetaxel vs. Docetaxel in EGFR Wild-Type NSCLC after Progression on Platinum-based Therapy
  • Plinabulin/Docetaxel Combination Significantly Improved Overall Survival (OS), Progression Free Survival (PFS), Objective Response Rate (ORR), 2- and 3-year OS Rates and Significantly Reduced Grade 4 Neutropenia vs. Docetaxel
Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment